Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Vertex Pharmaceuticals Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Shareholders’ equity1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 16, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
- Share Price
- The share price exhibits considerable volatility throughout the observed period. Initially, it declines from $39.49 in 2006 to a low of $18.21 in 2008, followed by a recovery and overall upward trend. From 2009 onward, the share price generally increases, reaching notable peaks at $160.94 in 2018 and continuing to rise to $462.58 by 2025. Despite some fluctuations, the overall trajectory is strongly positive, indicating growing market confidence or fundamental improvements.
- Book Value per Share (BVPS)
- The book value per share starts at $2.18 in 2006 and shows mixed fluctuations in early years, decreasing to as low as $1.57 in 2009. From 2010 onward, there is a consistent and substantial increase, peaking at $68.06 in 2024 before a slight decline to $63.9 in 2025. This upward trend suggests strengthening equity base and accumulation of assets relative to shares outstanding during the latter part of the period. The variability in early years may reflect operational or investment phases.
- Price-to-Book Value Ratio (P/BV)
- The P/BV ratio experiences significant swings, beginning at a very high level of 18.12 in 2006, dropping to 7.52 and 8.92 in subsequent years, then surging dramatically to 21.09 in 2009. Afterward, the ratio generally declines with intermittent rises, falling to its lowest point of 5.5 in 2023. A slight increase occurs again toward 2025, ending at 7.24. This pattern implies that the market price relative to book value became more moderate over time, potentially reflecting more balanced valuation relative to the company’s equity or improving asset quality. Early volatility in ratio values may be linked to share price instability and changes in book value per share.
- Overall Observations
- The data indicates a company that experienced initial instability followed by substantial growth in both market valuation and equity base. The share price’s strong appreciation post-2009 matches an increasing book value per share, suggesting real growth in shareholder value rather than speculative spikes alone. The declining P/BV ratio over time suggests market valuations became more grounded relative to book value, potentially indicating maturation in market perception. The minor decline in book value and slight uptick in P/BV towards 2025 could warrant monitoring for changes in asset base or investor sentiment.
Comparison to Competitors
Vertex Pharmaceuticals Inc., P/BV, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | ||||||||||||
| Feb 15, 2024 | ||||||||||||
| Feb 10, 2023 | ||||||||||||
| Feb 9, 2022 | ||||||||||||
| Feb 11, 2021 | ||||||||||||
| Feb 13, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 15, 2018 | ||||||||||||
| Feb 23, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 13, 2015 | ||||||||||||
| Feb 11, 2014 | ||||||||||||
| Mar 1, 2013 | ||||||||||||
| Feb 22, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 19, 2010 | ||||||||||||
| Feb 17, 2009 | ||||||||||||
| Feb 11, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., P/BV, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).